Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Abstract

WOS: 000560368300103[No abstract available]Merck Co., Inc.Merck & CompanyMerck & Co., Inc